This is an accepted manuscript of an article published by Taylor & Francis in Pharmaceutical Development and Technology on 20 Oct 2020, available online at: http://www.tandfonline.com/10.1080/10837450.2020.1839496 The accepted version of the publication may differ from the final published version.There is a need to accelerate paediatric formulation evaluation and enhance quality of early stage data in drug development to alleviate the information pinch point present between formulation development and clinical evaluation. This present work reports application of DNA microarrays as a high throughput screening tool identifying markers for prediction of bioavailability and formulation driven physiological responses. With a focus on enhancing...
Background and aim: The aim of this project was to conduct a systematic review of the current litera...
Drug discovery and development advances in the last decades allowed to find a treatment for many pre...
Improved global access to novel age-appropriate formulations for paediatric subsets, either of new c...
There is a need to accelerate paediatric formulation evaluation and enhance quality of early stage d...
Angiotensin converting enzyme (ACE) inhibitors lisinopril and ramipril were selected from EMA/480197...
TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazon...
Here we describe a collaboration between industry, the National Health Service (NHS) and academia th...
Dissolution studies have become of great significance because, in most cases, drug dissolution is th...
The disposition of a drug is driven by various processes, such as drug metabolism, drug transport, g...
Quantitative and qualitative differences in drug metabolizing enzymes (DMEs) from birth to adulthood...
Profound changes in drug metabolizing enzyme expression occurs during development that impacts drug ...
The complex process of oral drug absorption is influenced by a host of drug and formulation properti...
This article aims to provide an overview of the current situation regarding pharmacogenetic and phar...
Improved global access to novel age-appropriate formulations for paediatric subsets, either of new c...
The modulation of drug metabolism enzyme (DME) expression by therapeutic agents is a central mechani...
Background and aim: The aim of this project was to conduct a systematic review of the current litera...
Drug discovery and development advances in the last decades allowed to find a treatment for many pre...
Improved global access to novel age-appropriate formulations for paediatric subsets, either of new c...
There is a need to accelerate paediatric formulation evaluation and enhance quality of early stage d...
Angiotensin converting enzyme (ACE) inhibitors lisinopril and ramipril were selected from EMA/480197...
TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazon...
Here we describe a collaboration between industry, the National Health Service (NHS) and academia th...
Dissolution studies have become of great significance because, in most cases, drug dissolution is th...
The disposition of a drug is driven by various processes, such as drug metabolism, drug transport, g...
Quantitative and qualitative differences in drug metabolizing enzymes (DMEs) from birth to adulthood...
Profound changes in drug metabolizing enzyme expression occurs during development that impacts drug ...
The complex process of oral drug absorption is influenced by a host of drug and formulation properti...
This article aims to provide an overview of the current situation regarding pharmacogenetic and phar...
Improved global access to novel age-appropriate formulations for paediatric subsets, either of new c...
The modulation of drug metabolism enzyme (DME) expression by therapeutic agents is a central mechani...
Background and aim: The aim of this project was to conduct a systematic review of the current litera...
Drug discovery and development advances in the last decades allowed to find a treatment for many pre...
Improved global access to novel age-appropriate formulations for paediatric subsets, either of new c...